{"id":"ziltivekimab-b","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to IL-1β and preventing its interaction with the IL-1 receptor, thereby reducing inflammation and modulating the immune response.","oneSentence":"Ziltivekimab B is an interleukin-1 beta (IL-1β) inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:25.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of generalized pustular psoriasis"}]},"trialDetails":[{"nctId":"NCT05721989","phase":"PHASE1","title":"A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-02-03","conditions":"Healthy Participants","enrollment":267},{"nctId":"NCT05021835","phase":"PHASE3","title":"ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2021-08-30","conditions":"Cardiovascular Risk, Chronic Kidney Disease, Inflammation","enrollment":6200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ziltivekimab B","genericName":"Ziltivekimab B","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ziltivekimab B is an interleukin-6 inhibitor, classified as an antibody and inhibitor drug modality. It is being studied in clinical trials for various conditions, including cardiovascular risk, chronic kidney disease, and inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}